Tissue Regeneration Therapeutics Inc. (TRT) is a progressive biotechnology company with a focus on the commercial development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology. By providing license opportunities to collaborating partner companies we create cell and regenerative strategies that maximize the utility of publicly sourced tissue – for therapies that address important health care issues of today. TRT has discovered the world’s richest source of mesenchymal stem cells (MSCs) with potent regenerative, angiogenic, anti-inflammatory and immuno-regulatory properties; and is the first company in the world to have issued and allowed patents in US and Europe for extraction of these unique cells from umbilical cord tissue. Together, we build very powerful biology.